Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$3.5 million.

  • Sutro Biopharma's Change in Accured Expenses fell 18370.01% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 7954.08%. This contributed to the annual value of -$7.4 million for FY2024, which is 12906.72% down from last year.
  • As of Q3 2025, Sutro Biopharma's Change in Accured Expenses stood at -$3.5 million, which was down 18370.01% from $1.6 million recorded in Q2 2025.
  • Sutro Biopharma's 5-year Change in Accured Expenses high stood at $20.7 million for Q4 2023, and its period low was -$7.6 million during Q1 2024.
  • For the 5-year period, Sutro Biopharma's Change in Accured Expenses averaged around $1.8 million, with its median value being $2.2 million (2024).
  • Per our database at Business Quant, Sutro Biopharma's Change in Accured Expenses soared by 29596.79% in 2023 and then tumbled by 18370.01% in 2025.
  • Sutro Biopharma's Change in Accured Expenses (Quarter) stood at $5.2 million in 2021, then decreased by 0.08% to $5.2 million in 2022, then soared by 295.97% to $20.7 million in 2023, then plummeted by 103.59% to -$744000.0 in 2024, then plummeted by 367.88% to -$3.5 million in 2025.
  • Its last three reported values are -$3.5 million in Q3 2025, $1.6 million for Q2 2025, and $5.6 million during Q1 2025.